M
Matthew McIntosh
Publications - 11
Citations - 2570
Matthew McIntosh is an academic researcher. The author has contributed to research in topics: Transplantation & Survival analysis. The author has an hindex of 9, co-authored 11 publications receiving 2490 citations.
Papers
More filters
Journal ArticleDOI
Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996
Sundaram Hariharan,Christopher P. Johnson,Barbara A. Bresnahan,S. Taranto,Matthew McIntosh,Donald Stablein +5 more
TL;DR: There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.
Journal ArticleDOI
Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal Disease: Report of the NIH IG02 Trial
Stanley C. Jordan,Stanley C. Jordan,Dolly B. Tyan,Don M. Stablein,Matthew McIntosh,Steve Rose,Ashley Vo,Mieko Toyoda,Connie L. Davis,Ron Shapiro,Deborah Adey,Dawn S. Milliner,Ralph J. Graff,Robert W. Steiner,Gaetano Ciancio,Shobah Sahney,Jimmy A. Light +16 more
TL;DR: It is concluded that IVIG is better than placebo in reducing anti-HLA antibody levels and improving transplantation rates in highly sensitized patients with ESRD awaiting kidney transplants.
Journal ArticleDOI
Prednisone withdrawal, in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
Nasimul Ahsan,Donald E. Hricik,Arthur J. Matas,Stephen Rose,Stephen J. Tomlanovich,Alan H. Wilkinson,Marian Ewell,Matthew McIntosh,Donald Stablein,Ernest E. Hodge,Daniel H. Hayes,Paul F. Gores,David M. Cohen,Thomas A. Gonwa,Karl Brinler,Robert C. Harland,John F. Neylan,Mark D. Pescovitz,James J. Wynn,Harold C-Yang,William M. Bennett,John B. Copley,John Dunn,S. Tomlanovich,Lawrence Chan,J. Andrew Bertolatus,Mathew R. Weir,Robert Mendez,John D. Pirsch,J. Harold Helderman +29 more
TL;DR: For recipients on cyclosporine/mycophenolate mofetil/P with no AR at 90 days, the chance of developing subsequent AR is small; if P is tapered and withdrawn, the risk increases, but the majority remain free of acute and chronic rejection.
Journal ArticleDOI
Safety and Efficacy of a Calcineurin Inhibitor Avoidance Regimen in Pediatric Renal Transplantation
William E. Harmon,Kevin E.C. Meyers,Julie R. Ingelfinger,Ruth A. McDonald,Matthew McIntosh,Martin Ho,Leslie Spaneas,Jo Ann Palmer,Marena Hawk,Chris S. Geehan,Kathryn Tinckam,Wayne W. Hancock,Mohamed H. Sayegh +12 more
TL;DR: It is concluded that calcineurin inhibitor-free immunosuppression can be safe and effective in pediatric living-donor renal transplantation, however, further modifications that are designed to lessen early rejection rates and decrease complications should be tested before this approach is used routinely.
Journal ArticleDOI
A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation.
Mark R. Benfield,Amir Tejani,William E. Harmon,Ruth A. McDonald,Donald Stablein,Matthew McIntosh,Stephen Rose +6 more
TL;DR: It is demonstrated that the incidence of acute rejection or graft failure in pediatric patients is not improved by OKT3 induction therapy relative to cyclosporine induction, and graft survival was inferior for children aged 6’yr or younger.